Company Hyloris Pharmaceuticals SA

Equities

HYL

BE0974363955

Pharmaceuticals

Market Closed - Euronext Bruxelles 12:35:26 2024-03-28 pm EDT 5-day change 1st Jan Change
11.45 EUR +3.62% Intraday chart for Hyloris Pharmaceuticals SA +3.15% -10.20%

Business Summary

Hyloris Pharmaceuticals SA is a specialty biopharma company identifying and unlocking hidden potential in existing medications for the benefit of patients and the healthcare system. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad proprietary product pipeline that has the potential to offer significant advantages over currently available alternatives. Hyloris Pharmaceuticals SA currently has two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid analgesic for the treatment of pain. The Company's development strategy primarily focuses on the FDA's 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule has already been established.

Number of employees: 42

Sales per Business

EUR in Million2021Weight2022Weight Delta
Pharmaceuticals
100.0 %
3 100.0 % 3 100.0 % -4.68%

Sales per region

EUR in Million2021Weight2022Weight Delta
Belgium
100.0 %
3 100.0 % 3 100.0 % -4.68%

Managers

Managers TitleAgeSince
Founder 50 11-12-31
Founder 48 11-12-31
Director of Finance/CFO 53 21-09-22
Chief Operating Officer - 20-09-30
Investor Relations Contact - -
General Counsel 63 19-12-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 66 19-12-31
Director/Board Member 74 19-12-31
Director/Board Member 75 19-12-31
Director/Board Member 59 -
Founder 48 11-12-31
Chairman 62 19-09-30
Director/Board Member - 19-12-31
Founder 50 11-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 28,000,374 12,146,562 ( 43.38 %) 0 43.38 %

Shareholders

NameEquities%Valuation
7,676,400 27.42 % 102 M €
3,657,505 13.06 % 48 M €
1,708,022 6.100 % 23 M €
1,610,021 5.750 % 21 M €
915,612 3.270 % 12 M €
Mandarine Gestion SA
0.1518 %
42,500 0.1518 % 563 394 €
Claresco Finance SA
0.007143 %
2,000 0.007143 % 26 513 €
DFA Australia Ltd.
0.002796 %
783 0.002796 % 10 380 €

Company contact information

Hyloris Pharmaceuticals SA

Boulevard Patience et Beaujonc N°3/1

4000, Liege

+32 4 346 02 07

http://www.hyloris.com
address Hyloris Pharmaceuticals SA(HYL)
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.45 EUR
Average target price
20.65 EUR
Spread / Average Target
+80.35%
Consensus

Annual profits - Rate of surprise